Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High - Still a Buy?

Key Points

• Kiniksa Pharmaceuticals hit a new 52-week high of $82.98, trading near $80.89 and valuing the company at approximately $6.26 billion.
• Analyst sentiment remains favorable: eight analysts rate the stock a Buy and one a Hold, producing a “Moderate Buy” consensus and an average price target of $93.14.
• The company met quarterly EPS expectations at $0.30 and exceeded revenue forecasts with $243.6 million, while insiders recently sold shares and institutional investors own about 53.95% of the stock.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) reached a new 52-week high on Thursday. The company traded as high as $82.98 and last traded at $80.8850, with a volume of 226,231 shares trading hands. The stock had previously closed at $78.84.

Analyst Ratings Changes

KNSA has been the topic of several analyst reports. Weiss Ratings raised Kiniksa Pharmaceuticals International from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Wells Fargo & Company started coverage on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, September 30th. They set an "overweight" rating and a $87.00 price target for the company. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Finally, Wedbush upped their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of "Moderate Buy" and a consensus price target of $93.14.

Kiniksa Pharmaceuticals International Stock Performance

The firm has a market cap of $6.26 billion, a P/E ratio of 82.73 and a beta of 0.04. The company's 50 day moving average is $77.75 and its 200 day moving average is $63.60.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the business's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director owned 11,672 shares in the company, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 51.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Allworth Financial LP increased its position in Kiniksa Pharmaceuticals International by 42.0% during the 2nd quarter. Allworth Financial LP now owns 453 shares of the company's stock valued at $29,000 after purchasing an additional 134 shares during the period. Arizona State Retirement System raised its holdings in Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company's stock worth $648,000 after purchasing an additional 209 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 21.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company's stock worth $95,000 after purchasing an additional 223 shares during the period. First Trust Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals International by 3.1% in the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company's stock worth $476,000 after purchasing an additional 293 shares during the period. Finally, Nykredit A S acquired a new position in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $34,000. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for patients with debilitating diseases, including conditions driven by immune-system and inflammatory responses. The company's strategy centers on targeted medicines intended to address significant unmet medical needs in specialty markets.

Kiniksa's primary commercial product is ARCALYST (rilonacept), an interleukin-1 blocker. In the United States, ARCALYST is approved for the treatment of recurrent pericarditis and for reducing the risk of recurrence in adults and children age 12 and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.